⌘K

Login Start Free

Home/Filings/4/0001415889-24-028567

4//SEC Filing

Chakma Justin 4

Accession 0001415889-24-028567

CIK 0001671858other

View on SEC.gov Company Profile

Filed

Dec 5, 7:00 PM ET

Accepted

Dec 6, 7:15 PM ET

Size

19.6 KB

Accession

0001415889-24-028567

Insider Transaction Report

Form 4

Period: 2024-12-04

ARS Pharmaceuticals, Inc.SPRY

Chief Business Officer

Transactions

Exercise/Conversion
Common Stock
2024-12-05$0.84/sh+49,640$41,698→ 186,020 total
Exercise/Conversion
Common Stock
2024-12-06$0.84/sh+50,000$42,000→ 186,380 total
Sale
Common Stock
2024-12-06$14.23/sh−50,000$711,615→ 136,380 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-12-05−49,640→ 100,000 total
Exercise: $0.84Exp: 2029-07-04→ Common Stock (49,640 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-12-06−50,000→ 50,000 total
Exercise: $0.84Exp: 2029-07-04→ Common Stock (50,000 underlying)
Exercise/Conversion
Common Stock
2024-12-04$0.84/sh+45,000$37,800→ 181,380 total
Sale
Common Stock
2024-12-04$13.95/sh−45,000$627,944→ 136,380 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-12-04−45,000→ 149,640 total
Exercise: $0.84Exp: 2029-07-04→ Common Stock (45,000 underlying)
Sale
Common Stock
2024-12-05$14.13/sh−49,640$701,642→ 136,380 total

Footnotes (4)

[F1]The weighted average sale price for the transaction reported was $13.9543, and the range of prices were between $13.77 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
[F2]The weighted average sale price for the transaction reported was $14.1346, and the range of prices were between $13.95 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
[F3]The weighted average sale price for the transaction reported was $14.2323, and the range of prices were between $14.00 and $14.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
[F4]Immediately exercisable.

Documents

1 file

4
form4-12072024_121247.xmlPrimary

Issuer

ARS Pharmaceuticals, Inc.

CIK 0001671858

Entity typeother

Related Parties

1

filerCIK 0001951238

Filing Metadata

Form type: 4
Filed: Dec 5, 7:00 PM ET
Accepted: Dec 6, 7:15 PM ET
Size: 19.6 KB

View on SEC.gov